In a Chinese trial, trastuzumab rezetecan induced a 73% response rate in previously treated HER2-mutant non-small cell lung cancer (NSCLC). The safety profile of the novel antibody-drug conjugate ...

In the landmark CLEOPATRA study (NCT00567190), THP significantly improved median overall survival (OS) from 40.8 months (95% CI, 35.8-48.3) with placebo, trastuzumab, and docetaxel to 56.5 months ...

The key limitations of the present study are the open-label design, enrollment of only Japanese patients, ... 1767P Co-clinical PDX study of trastuzumab deruxtecan in HER2-positive uterine ...

SAN ANTONIO — Fam-trastuzumab deruxtecan-nxki induced encouraging response rates among certain patients with early breast cancer, according to findings presented at San Antonio Breast Cancer ...

Topline data were announced from a phase 3 trial evaluating fam-trastuzumab deruxtecan-nxki followed by THP in patients with high-risk, locally advanced HER2-positive early stage breast cancer.

Trastuzumab deruxtecan improves survival in second- and later-line settings. ... In the DESTINY-Breast02 study, ... "All had prior trastuzumab and T-DM1 by design, ...

Patients with localized, hormone receptor-positive, HER2-low breast cancer treated with trastuzumab deruxtecan (T-DXd, Enhertu) in the neoadjuvant setting had an overall response rate of 75 ...

Background: Trastuzumab deruxtecan (T-DXd) is a novel antibody-drug conjugate (ADC) showing significant promise in treatment of metastatic HER2+ and HER2-low breast cancer. This systematic review and ...

The study randomized 1157 patients to three treatment groups: T-DXd 5.4 mg/kg every three weeks plus placebo, T-DXd-pertuzumab, or a taxane plus trastuzumab with pertuzumab (THP).

The median OS when using trastuzumab deruxtecan was 14.7 months compared to 11.4 months for the current standard treatment approach. Using the drug also reduced the risk of death by nearly 30% and ...

In the DESTINY-Breast04 study, the advantage of treatment with trastuzumab deruxtecan in patients with HER2-low tumors was shown in overall survival in particular: The median survival of patients ...